3581. Anti-Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia.
作者: Soravis Osataphan.;Maria Vamvini.;Evan D Rosen.;Lei Pei.;Natanie Erlikh.;Gurcharan Singh.;Poojaben Dhorajiya.;J Anthony Parker.;Jonathan M Dreyfuss.;Ahmed Rattani.;Mary-Elizabeth Patti.
来源: N Engl J Med. 2023年389卷8期767-769页 3588. Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda.
作者: Melissa D Conrad.;Victor Asua.;Shreeya Garg.;David Giesbrecht.;Karamoko Niaré.;Sawyer Smith.;Jane F Namuganga.;Thomas Katairo.;Jennifer Legac.;Rebecca M Crudale.;Patrick K Tumwebaze.;Samuel L Nsobya.;Roland A Cooper.;Moses R Kamya.;Grant Dorsey.;Jeffrey A Bailey.;Philip J Rosenthal.
来源: N Engl J Med. 2023年389卷8期722-732页
Partial resistance of Plasmodium falciparum to the artemisinin component of artemisinin-based combination therapies, the most important malaria drugs, emerged in Southeast Asia and now threatens East Africa. Partial resistance, which manifests as delayed clearance after therapy, is mediated principally by mutations in the kelch protein K13 (PfK13). Limited longitudinal data are available on the emergence and spread of artemisinin resistance in Africa.
3589. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
作者: Adrian Sacher.;Patricia LoRusso.;Manish R Patel.;Wilson H Miller.;Elena Garralda.;Martin D Forster.;Armando Santoro.;Alejandro Falcon.;Tae Won Kim.;Luis Paz-Ares.;Samantha Bowyer.;Maria de Miguel.;Sae-Won Han.;Matthew G Krebs.;Jong-Seok Lee.;Michael L Cheng.;Kathryn Arbour.;Erminia Massarelli.;Yoonha Choi.;Zhen Shi.;Sandhya Mandlekar.;Mark T Lin.;Stephanie Royer-Joo.;Julie Chang.;Neekesh V Dharia.;Jennifer L Schutzman.;Jayesh Desai.; .
来源: N Engl J Med. 2023年389卷8期710-721页
Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity.
|